Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Disopyramide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Disopyramide SCHEMBL23931452 | 1.00 | KCNH2 (1.00) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| (S)-Disopyramide SCHEMBL41811 | 1.00 | KCNH2 (1.00) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| Disopyramide SCHEMBL546251 | 0.99 | KCNH2 (0.98) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| Disopyramide SCHEMBL9097836 | 0.96 | KCNH2 (0.93) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| Disopyramide SCHEMBL41810 | 0.95 | KCNH2 (0.91) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| Disopyramide SCHEMBL5167606 | 0.95 | KCNH2 (0.91) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| Disopyramide SCHEMBL8511308 | 0.94 | KCNH2 (0.89) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| SCHEMBL10945741 | 0.93 | KCNH2 (0.87) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| Disopyramide SCHEMBL20770785 | 0.92 | KCNH2 (0.85) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| SCHEMBL10798660 | 0.92 | KCNH2 (0.85) | KCNH2BLMOPRK1SLC22A2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11995 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4731002-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260097021-A1 | METHODS FOR TREATING HYPERTROPHIC CARDIOMYOPATHY | CYTOKINETICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | CELLTRION INC. (KR) | 2026-02-17 | — | — | US | claimed |
| US-12474326-B2 | Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications | TABULA RASA HEALTHCARE, INC. (US) | 2025-11-18 | — | — | US | claimed |
| US-12419863-B2 | Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy | CELLTRION INC. (KR) | 2025-09-23 | — | — | US | claimed |
| EP-4590681-A1 | CARDIOPROTECTIVE LIPID AND METHOD OF USE | Signpath Pharma, Inc. (US) | 2025-07-30 | — | — | EP | claimed |
| US-4470987-A | Process for treatment and prevention of ventricular fibrillation | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1984-09-11 | — | — | US | claimed |
| EP-0113100-A2 | Disopyramide immunogens, antibodies, labeled conjugates, and related derivatives | MILES LABORATORIES, INC. (US) | 1984-07-11 | — | — | EP | claimed |
| EP-0014569-B1 | (-)-ALPHA-(2-(BIS(1-METHYLETHYL)AMINO)ETHYL)-ALPHA-PHENYL-2-PYRIDINEACETAMIDE AND PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PRODUCTION THEREOF AND COMPOSITIONS CONTAINING THE SAME | G.D. Searle & Co. (US) | 1983-07-13 | — | — | EP | claimed |
| EP-0080341-A2 | Pharmaceutical multiple-units formulation | A/S Alfred Benzon (DK) | 1983-06-01 | — | — | EP | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| EP-0044441-A1 | Monoclonal antibodies to drugs, methods for their production and somatic cell hybridomas secreting them | MILES LABORATORIES, INC. (US) | 1982-01-27 | — | — | EP | claimed |
| US-4288553-A | Disopyramide compounds for conjugating proteins used in immunoassays for disopyramide | SYVA COMPANY (US) | 1981-09-08 | — | — | US | claimed |
| US-4279992-A | Specific binding assay employing an enzyme-cleavable substrate as label | MILES LABORATORIES, INC. (US) | 1981-07-21 | — | — | US | claimed |
| US-4255582-A | (-)-α-{2-[Bis(1-methylethyl)amino]ethyl}-.alpha.-phenyl-2-pyridineacetamide and pharmacologically acceptable salts thereof | G. D. SEARLE & CO. (US) | 1981-03-10 | — | — | US | claimed |
| EP-0014569-A2 | (-)-Alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-2-pyridineacetamide and pharmacologically acceptable salts thereof, process for the production thereof and compositions containing the same | G.D. Searle & Co. (US) | 1980-08-20 | — | — | EP | claimed |